Journal
VACCINES
Volume 8, Issue 3, Pages -Publisher
MDPI
DOI: 10.3390/vaccines8030404
Keywords
SARS-CoV-2; COVID-19; nucleic acid tests; serology; vaccination; immunity
Categories
Funding
- Swiss National Science Foundation (SNF) [31003A 149925, 310030-179459]
- University of Lausanne, Switzerland
- International Immunology Centre, Anhui Agricultural University, Hefei, China
- University of Bern, Switzerland
Ask authors/readers for more resources
Vaccines are needed to protect from SARS-CoV-2, the virus causing COVID-19. Vaccines that induce large quantities of high affinity virus-neutralizing antibodies may optimally prevent infection and avoid unfavorable effects. Vaccination trials require precise clinical management, complemented with detailed evaluation of safety and immune responses. Here, we review the pros and cons of available vaccine platforms and options to accelerate vaccine development towards the safe immunization of the world's population against SARS-CoV-2. Favorable vaccines, used in well-designed vaccination strategies, may be critical for limiting harm and promoting trust and a long-term return to normal public life and economy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available